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Pleural effusionAbstract Objectives: Todetermine the level of interleukin-6 (IL-6) in both serumandpleural ﬂuid in
order to evaluate the diagnostic utility of IL-6 in differentiation between different types of pleural effu-
sion.
Background: Pleural effusion is a relatively common clinical condition. It is often diagnostic
dilemma for the physician. Interleukin-6 (IL-6) has multiple functions on various cells and tissues.
It is often used as a marker for systemic activation of pro-inﬂammatory cytokines.
Methods: This study was conducted on 40 patients of pleural effusion, they were selected from
Al-Mahalla Chest Hospital in the period between October 2012 and May 2013. All patients
were subjected to detailed clinical history, thorough clinical examination, plain chest-X-ray
(postero-anterior and lateral views), blood sample for: Complete blood picture (CBC), erythrocyte
sedimentation rate (ESR), liver functions, renal functions and serum and pleural ﬂuid (LDH,
protein and IL-6) by ELISA.
Results: Serum and effusion IL-6 could differentiate between exudate transudate as it increased in
exudate than transudate. In the present study there was higher concentration of IL-6 in the serum and
pleural effusion of parapneumonic effusion than malignant and tuberculous exudative pleural effu-
sion and higher concentration in malignant than tuberculous effusion.
Conclusion: Effusion IL-6 could be used to differentiate between exudate and transudate and
serum IL-6 could be used as an alternative non invasive method for differentiation between
exudates and transudate as there was a signiﬁcant positive correlation between serum IL-6 and
effusion IL-6.
ª 2015 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis.Introduction
Pleural effusion occurs in a great variety of abnormalities.
Even exhaustive diagnostic tests fail to reveal the etiology in
about 20 percent of the cases [1]. Distinguishing an exudate
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pleural effusion. Pleural ﬂuid is enriched in proteins, inﬂamma-
tory cells, and mediators [2]. Cytokines-producing cells and
cytokines have been reported in pleural effusion from patients
with malignant diseases, tuberculosis and empyema [3].
Tuberculous pleurisy (TBP) is a common cause of pleural
effusion in areas with high disease prevalence, the diagnosis
of TBP represents largely an immunological reaction in which
a repertoire of cytokines is involved in pathogenesis. These
include especially interleukin (IL) IL-22, IL-6, IL-8, tumor
necrosis factor-alpha (TNF-a), and interferon gamma
(INF-c) [4]. The pleiotropic cytokine interleukin-6 (IL-6) is a
major marker of systemic response to inﬂammatory process
and is involved in the regulation of a variety of cellular
responses [5].
Aim of the study
The aim of this work is to determine the level of interleukin-6
(IL-6) in both serum and pleural ﬂuid in order to evaluate the
diagnostic utility of IL-6 in differentiation between different
types of pleural effusion.
Methods
A written consent was obtained from all subjects prior to
inclusion and the regional ethics committee of the Menouﬁa
University hospital approved the study. The study was con-
ducted in Al-Mahalla chest hospital during the period between
October 2012 and May 2013. The study involved forty patients
with pleural effusion; their ages ranged from 25 to 75 years. 15
were females and 25 were males.
Study subjects were divided into two groups: Group I:
included 15 cases with transudative pleural effusion, and clas-
siﬁed into Group Ia: 6 cases with transudative pleural effusions
due to liver cell failure. Group Ib: 6 cases with transudative
pleural effusions due to heart failure. Group Ic: 2 cases with
transudative pleural effusions due to combined heart and liver
cell failure. Their ages ranged from 54 to 65 years And 1 case
due to renal failure. Group II: This group included 25 cases
with exudative pleural effusion. This group was subdivided
into: Group IIa: 4 cases with exudative tuberculous effusions,
1 male and 3 females. Group IIb: 6 cases with exudative para-
pneumonic pleural effusions, 5 cases were males and 1 female.
Group IIc: 10 cases with exudative malignant pleural effusions,
8 cases were males and 2 females. 2 cases were with exudativeTable 1 Comparison between patients with transudative effusion an
protein (g/dl), LDH (u/dl) and IL-6 (u/ml).
Transudate (n= 15)
Range Mean ± SD
Serum protein (g/dl) 5.9–8.1 6.665 ± 0.661
Pleural ﬂuid protein (g/dl) 1.2–4.1 2.3 ± 0.9
Serum LDH (u/dl) 87–319 199.33 ± 87.15
Pleural ﬂuid LDH (u/dl) 109–552 318.3 ± 139.9
Serum IL-6 (pg/ml) 19–37 26.9 ± 5.7
Pleural ﬂuid IL-6 (pg/ml) 91–530 254.1 ± 136.4
* Means signiﬁcant.
** Means highly signiﬁcant.collagen pleural effusions. 1 case was with exudative effusion
due to pulmonary embolism. 1 case was with exudative pleural
effusions due to cholecystectomy operation. 1 case was with
exudative pleural effusion due to Meig’s syndrome.
All subjects were subjected to: detailed clinical history,
thorough clinical examination, plain chest-X-ray, blood
sample for: CBC, ESR, liver functions, renal functions, serum
and pleural effusion (LDH, protein and serum and IL-6).
Results
There was a statistically highly signiﬁcant difference
between patients with transudative and exudative pleural
effusion as regards pleural ﬂuid protein, serum LDH, pleural
ﬂuid LDH and pleural ﬂuid IL-6 (P 6 0.001), and a non
statistically signiﬁcant difference between both groups as
regards serum protein (P> 0.05), and signiﬁcant difference
between the two groups as regards serum IL-6 (as shown in
Table 1).
This study showed a statistically signiﬁcant increase in
serum and effusion LDH and highly signiﬁcant increase in
effusion IL-6 in patients with transudative effusion due to liver
cell failure, and also showed a statistically signiﬁcant increase
in serum and effusion LDH in patients with transudative effu-
sion due to heart failure in comparison with liver cell failure,
while no statistically signiﬁcant difference in serum and
effusion LDH and effusion IL-6 in patients with transudative
effusion due to combined liver cell failure and heart failure
(as shown in Table 2).
This study showed that patients with parapneumonic effu-
sion had statistically signiﬁcantly higher pleural ﬂuid LDH and
IL-6 levels than non parapneumonic effusion while serum
pleural ﬂuid protein and serum LDH didn’t differ between
both groups (as shown in Table 3).
There was a highly signiﬁcant difference between malignant
and parapneumonic exudative pleural ﬂuid as regards effusion
LDH, there was a signiﬁcant difference between tuberculous
and parapneumonic exudative pleural effusion as regards
serum IL-6, there was a signiﬁcant difference between malig-
nant and parapneumonic exudative pleural ﬂuid as regards
effusion IL-6 and there is a highly signiﬁcant difference
between TB and parapneumonic exudative pleural effusion
as regards effusion IL-6 (as shown in Table 4).
There was a signiﬁcant positive correlation between serum
IL-6 and pleural ﬂuid protein and (serum and effusion)
LDH. And there was a signiﬁcant positive correlation betweend patients with exudative effusion as regards serum and effusion
Exudate (n= 25) T-test
Range Mean ± SD T P-value
6–7 6.5 ± 0.4 0.8 0.4
3–4.7 3.8 ± 0.45 7.03 0.000**
163–625 461.8–126.1 76 0.000**
315–1405 884.1 ± 276.3 7.4 0.000**
14.2–190 106.6 ± 53.9 5.7 0.03*
91–1900 863.9 ± 526.2 4.4 0.000**





Liver cell failure and
heart failure (n= 2)
ANOVA Tukey’s test
F P-value P1 P2 P3
Protein serum (g/dl) Mean 6.600 6.717 6.735 0.049 0.952
SD 0.800 0.700 0.092
Eﬀusion protein (g/dl) Mean 2.283 2.540 2.100 0.197 0.824
SD 0.915 0.936 1.273
Serum LDH (u/dl) Mean 252.333 148.833 91.000 6.176 0.016 0.05* 0.03* 0.54
SD 83.471 49.159 5.657
Eﬀusion LDH (u/dl) Mean 433.833 272.333 154.000 6.734 0.012 0.05* 0.02* 0.38
SD 95.451 118.155 63.640
Serum IL-6 (pg/ml) Mean 27.833 24.000 34.500 3.586 0.063
SD 5.269 4.690 3.536
Eﬀusion IL-6 (pg/ml) Mean 138.333 358.833 255.500 7.269 0.01 0.01** 0.36 0.44
SD 80.421 122.048 60.104
* Means signiﬁcant.
** Means highly signiﬁcant.
Table 3 Comparison between parapneumonic and non-parapneumonic exudative pleural effusion as regards (serum-effusion)
protein, (serum-effusion) LDH and (serum-effusion) IL-6.
Parapneumonic (n= 6) Non parapneumonic (n= 19) T-test
Mean ± SD Mean ± SD T P-value
Serum protein (g/dl) 6.550 ± 0.383 6.521 ± 0.363 0.168 0.868
Pleural ﬂuid protein (g/dl) 4.050 ± 0.351 3.693 ± 0.598 1.377 0.182
Serum LDH (u/dl) 492.333 ± 66.455 447.632 ± 139.705 0.749 0.461
Pleural ﬂuid LDH (u/dl) 1155.333 ± 215.543 777.053 ± 235.841 3.488 0.002*
Serum IL-6 (pg/ml) 141.500 ± 38.014 95.563 ± 54.301 1.916 0.068
Pleural ﬂuid IL-6 (pg/ml) 1437.667 ± 351.475 682.789 ± 436.320 3.844 0.001**
* Means signiﬁcant.
** Means highly signiﬁcant.
Table 4 Comparison between causes of exudative pleural effusions as regards (serum and effusion) protein, (serum and effusion)
LDH and (serum and effusion) IL-6.
ANOVA Tukey’s test
Mean ± SD F P-value Comparison P-value
Serum protein (gm/dl) Malignant 6.40 ± 0.37 0.38 0.69 Malignant & TB 0.79
TB 6.55 ± 0.42 Malignant & parapneumonic 0.73
Parapneumonic 6.55 ± 0.38 TB & parapneumonic 1
Pleural ﬂuid protein (gm/dl) Malignant 3.68 ± 0.46 1.99 0.17 Malignant & TB 0.34
TB 4.03 ± 0.31 Malignant & parapneumonic 0.21
Parapneumonic 4.05 ± 0.35 TB & parapneumonic 1
Serum LDH (u/dl) Malignant 470.70 ± 145.73 0.07 0.93 Malignant & TB 1
TB 473.25 ± 44.17 Malignant & parapneumonic 0.93
Parapneumonic 492.33 ± 66.45 TB & parapneumonic 0.96
Pleural ﬂuid LDH (u/dl) Malignant 809.90 ± 129.27 5.81 0.01 Malignant & TB 0.82
TB 881.00 ± 309.84 Malignant & parapneumonic 0.01**
Parapneumonic 1155.33 ± 215.54 TB & parapneumonic 0.11
Serum IL-6 (pg/ml) Malignant 108.10 ± 50.48 3.57 0.05 Malignant & TB 0.24
TB 62.55 ± 42.99 Malignant & parapneumonic 0.36
Parapneumonic 141.50 ± 38.01 TB & parapneumonic 0.04*
Pleural ﬂuid IL-6 (pg/ml) Malignant 839.00 ± 472.14 7.32 0.01 Malignant & TB 0.34
TB 493.75 ± 219.37 Malignant & parapneumonic 0.03*
Parapneumonic 1437.67 ± 351.47 TB & parapneumonic 0.01**
* Means signiﬁcant.
** Means highly signiﬁcant.
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Table 5 Correlation between serum and pleural effusion IL-6 and other markers.
Serum protein Eﬀusion protein Serum LDH Eﬀusion LDH Serum IL-6
Serum IL-6 R 0.13 0.45 0.78 0.78
P-value 0.42 0.003* 0000** 0000**
Eﬀusion IL-6 R 0.11 0.43 0.67 0.77 0.87
P-value 0.51 0.01** .0000** 0000** 0000**
* Means signiﬁcant.
** Means highly signiﬁcant.
176 M.A. Zamzam et al.pleural ﬂuid IL-6 and effusion protein (serum and effusion)
LDH and serum IL-6 (as shown in Table 5).
Discussion
Traditionally, pleural effusions have been separated into tran-
sudative and exudative effusions [6].
In the evaluation of a pleural effusion the ﬁrst step is to dif-
ferentiate between transudates and exudates, if the patient has
transudative effusion, no investigation needs to be directed
toward the pleura and the systemic condition can be treated
then the effusion will resolve. In contrast, if the patient has
exudative effusion, it is important to determine the local cause
that is responsible for effusion [6].
Cytokine-producing cells and cytokines have been reported
in pleural effusions from patients with malignant diseases,
tuberculosis, and empyema [3].
Interleukin-6 has long been regarded as a pro-inﬂammatory
cytokine induced by lipopolysaccharide along with TNF-a and
IL-1. IL-6 is often used as a marker for systemic activation of
pro-inﬂammatory cytokines [7].
This study was designed to assess the diagnostic value of
IL-6 in pleural effusion by estimation of its level in pleural
effusion and serum as the cytokine interleukin-6 is a major
marker of systemic response to inﬂammatory process and is
involved in the regulation of a variety of cellular responses
so used in differentiation between transudative and exudative
pleural effusion [3].
In this study there were high values in exudates than tran-
sudates as regards the pleural ﬂuid and serum LDH and IL-6
(as shown in Table 1).
These results agreed with Yokoyama et al. (1992), Ayoub
et al. (2007) and Akarsu et al. (2004) who stated that IL-6
levels in pleural ﬂuid are sensitive parameters to differentiate
exudates from transudates, they found that IL-6 level
increased in exudates than transudates [8–10].
On comparing between different etiologies of transudative
effusion, pleural ﬂuid due to heart failure had a signiﬁcantly
higher level of IL-6 than pleural ﬂuid due to liver cell failure
(as shown in Table 2).
As far as we know, no comparison between types of
transudative pleural effusion as regards IL-6 level was done
before but Chomeja et al. [12] estimated the concentrations
of IL-6 in pleural effusion and peripheral blood from patients
with tuberculosis, bronchial carcinoma and other carcinomas
as well as congestive heart failure (CHF) and pneumonias.
Quantitative analysis showed high concentrations of IL-6
only in parapneumonic pleural effusions. Lowest amounts
were detected in CHF indicating the non-inﬂammatory origin
of effusion.In the present study, pleural effusion IL-6 level was higher
in parapneumonic than non parapneumonic exudative effusion
(as shown in Table 2).
These results matched with Akarsu et al. (2004) study that
could differentiate between parapneumonic and non parap-
neumonic exudative effusion by estimation of effusion IL-6
level, this may be due to the continuing activation of the
macrophages by the bacterial lipopolysaccharide leading to
the release of cytokines (IL-1, TNF-a), which in turn promote
the production of IL-6 by the stroma cells in the cases of the
parapneumonic effusion [11].
In comparing the three types of exudates, in the present
study there was higher concentration of IL-6 in the serum
and pleural effusion of parapneumonic effusion than malig-
nant and tuberculous exudative pleural effusion and higher
concentration in malignant than tuberculous effusion (as
shown in Table 3).
Xirouchaki et al. (2002) found that pleural effusion IL-6
levels were signiﬁcantly higher in parapneumonic than in
malignant exudates that were matched with these results [3].
On the other hand, C¸igdem et al. [13], found that the tuber-
culous exudative pleural effusion had higher concentration of
IL-6 than malignant effusion, also Xirouchaki et al. (2002),
found that IL-6 level was signiﬁcantly higher in tuberculous
than in parapneumonic pleural ﬂuid [3].
This difference between the results of this study and
other studies may be due to large numbers of cases of
parapneumonic effusion than tuberculous and malignant
effusions.
In the present study there was a signiﬁcant positive correla-
tion between serum IL-6 and serum and effusion LDH and a
signiﬁcant positive correlation between effusion IL-6 and effu-
sion protein, serum and effusion LDH and serum IL-6 (as
shown in Table 5).
These results came in agreement with those of Yokoyama
et al. (1992), who stated that pleural ﬂuid IL-6 levels had
positive correlation with serum IL-6 levels as pleural IL-6
may leak to systemic circulation to increase serum IL-6 levels
[8].
Conclusion
From the present study we concluded that:
 Serum and effusion IL-6 could differentiate between exu-
dates and transudate as it increased in exudates than
transudate.
 IL-6 is an inﬂammatory marker and could differentiate
between parapneumonic and non parapneumonic exudative
effusion.
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tuberculous and non tuberculous pleural effusion.
 Serum and effusion IL-6 couldn’t differentiate between
malignant and non malignant exudative pleural effusion.
 Serum IL-6 could be used as an alternative non invasive
method which could differentiate between exudates and
transudate as there was a signiﬁcant positive correlation
between serum IL-6 and effusion IL-6.Conﬂict of interest
There is no conﬂict of interest.
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